medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Number 6

<< Back Next >>

Rev Invest Clin 2015; 67 (6)

Serous Cystadenomas Follow a Benign and Asymptomatic Course and Do Not Present a Significant Size Change During Follow-Up

Pelaez-Luna MC, Moctezuma-Velázquez C, Hernández-Calleros J, Uscanga-Domínguez LF

Language: English
References: 30
Page: 344-349
PDF size: 71.08 Kb.


ABSTRACT

Background: Serous cystadenoma is a benign pancreatic cystic neoplasm. Conservative management is favored. We studied the clinical characteristics and course of serous cystadenoma in patients undergoing surgery or conservative management only at an academic referral center. Methods: Patients presenting with serous cystadenoma in the years 2000-2013 were selected. Hospital records were evaluated for patient and serous cystadenoma characteristics. Results: A total of 22 patients with serous cystadenoma were identified. Mean age at diagnosis was 63 years and 82% were women. Diagnosis was incidental in 59%, and 18% presented with unspecific abdominal pain, 14% unexplained weight loss, 4.5% gastrointestinal obstructive symptoms, and 4.5% cholangitis. Location was pancreas body 36%, head 32%, tail 23%, and uncinate 9%. Mean serous cystadenoma diameter at diagnosis was 37 ± 23 mm. After diagnosis five patients underwent surgery. Initial size was similar between surgical and follow-up groups (p = 0.9). Four cases were lost to follow-up; 13 continued conservative management with a mean follow-up time of 54 ± 27 months. The initial and last serous cystadenoma size in the follow-up group remained similar (p = 0.9). Six cases presented significant tumor growth during follow-up (p › 0.05). All patients remained asymptomatic throughout follow-up. No malignancy or serous cystadenoma-related death occurred. Conclusions: Size change of serous cystadenoma was minimal and patients remained asymptomatic during follow-up. Surgery should be limited to symptomatic and selected cases.


REFERENCES

  1. Sahani DV, Dadavigere R, Saokar A, et al. Cystic pancreatic lesions: a simple imaging based classification system for guiding management. Radiographics. 2005;25:1471-84.

  2. Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al. 851 resected cystic tumors of the pancreas: A 33-year experience at the Massachusetts General Hospital. Surgery. 2012;152:s4-12.

  3. Abe H, Kubota K, Mori M, et al. Serous cystadenoma of the pancreas with invasive growth: benign or malignant? Am J Gastroenterol. 1998;93:1963-6.

  4. Strobel O, Z’graggen K, Schmitz-Winnenthal FH, et al. Risk of malignancy in serous cystic neoplasms of the pancreas. Digestion. 2003;68:24-33.

  5. Yoshimi N, Sugie S, Tanaka T, et al. A rare case of serous cystadenocarcinoma of the pancreas. Cancer. 1992;69:2449-53.

  6. Tseng JF, Warshaw AL, Sahani DV, Lauwers GY, Rattner DW, Fernandez del Castillo C. Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg. 2005;31:507-35.

  7. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high risk surgery. N Eng J Med. 2011;364:2128-37.

  8. Schmidt CM, Turrini O, Parikh P, et al. Effect of hospital volume, surgeon experience and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single institution experience. Arch Surg. 2010;145:634-40.

  9. van der Gaag NA, Berkhemer OA, Sprangers MA, et al. Quality of life and functional outcome after resection of pancreatic cystic neoplasms. Pancreas. 2014;43:755-61.

  10. Bhayani NH, Enomoto LM, James BC, et al. Multivisceral and extended resections during pancreatoduodenectomy increase morbidity and mortality. Surgery. 2014;155:567-74.

  11. Sikkens EC, Cahen DL, de Witt J, Looman CW, van Eijck C, Bruno MJ. Prospective assessment of the influence of pancreatic cancer resection on exocrine pancreatic function. Br J Surg. 2014;101:109-13.

  12. El-Hayek KM, Brown N, O’Rourke C, Falk G, Morris-Stiff G, Walsh M. Rate of growth of pancreatic serous cystadenoma as an indication for resection. Surgery. 2013;154:794-802.

  13. Jais B, Rebours V, Malleo G, et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut. 2016;65:305-12.

  14. van der Waaij LA, Van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc. 2005;62:383-9.

  15. Compagno J, Oertel JE. Microcystic adenomas of the pancreas (glycogen-rich cystadenomas): a clinicopathologic study of 34 cases. Am J Clin Pathol. 1978;69:573-80.

  16. Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw AL. Cystic neoplasms of the pancreas. N Eng J Med. 2004;351:1218-26.

  17. Sheehan MK, Beck K, Pickleman J, Aranha GV. Spectrum of cystic neoplasms of the pancreas and their surgical management. Arch Surg. 2003;138:657-60.

  18. Chen F, Liang Jy, Zhao QY, et al. Differentiation of branch duct intraductal papillary mucinous neoplasms from serous cystadenomas of the pancreas using contrast-enhanced sonography. J Ultrasound Med. 2014;33:449-55.

  19. Belsley NA, Pitman MB, Lauwers GY, Brugge WR, Deshpande V. Serous cystadenoma of the pancreas: limitations and pitfalls of endoscopic ultrasound guided fine needle aspiration biopsy. Cancer. 2008;114:102-10.

  20. Salomao M, Remotti H, Allendorf JD, et al. Fine needle aspirations of pancreatic serous cystadenomas: Improving diagnostic yield with cell blocks and a-inhibin immunohistochemistry. Cancer Cytopathol. 2014;122:33-9.

  21. Pelaez-Luna M, Chari ST. Cyst fluid analysis to diagnose pancreatic cystic lesions: an as yet unfulfilled promise. Gastroenterology. 2006;130:1007-9.

  22. Chu LC, Singhi AD, Hruban RH, Fishman EK. Characterization of pancreatic serous cystadenoma on dual phase multidetector computed tomography. J Comput Assist Tomogr. 2014;38:258-63.

  23. Kishida Y, Matsubayashi H, Okamura Y, et al. A case of solid type serous cystadenoma mimicking neuroendocrine tumor of the pancreas. J Dig Dis. 2014;15:211-15.

  24. Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, Sarr MG. Primary pancreatic cystic neoplasms revisited. Part I: serous cystic neoplasms. Surg Oncol. 2011;21:153-63.

  25. Leite I, Palmerio M, Farchione A, et al. Unilocular macrocystic serous cystadenoma of the pancreas—atypical features: a case report. Clin Imaging. 2014;38:336-9.

  26. Khashab MA, Shin EJ, Amateau S, et al. Tumor size and location correlate with behavior of pancreatic serous cystic neoplasms. Am J Gastroenterol. 2011;106:1521-6.

  27. Kimura W, Moriya T, Hirai I, et al. Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas. 2012; 41:380-7.

  28. Galanis C, Zamani A, Cameron JL, et al. Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. J Gastrointest Surg. 2007; 11:820-6.

  29. Bose D, Tam E, Liu J, et al. Multidisciplinary management strategy for incidental cystic lesions of the pancreas. J Am Coll Surg. 2010;211:205-15.

  30. Oh HC, Brugge WR. EUS guided pancreatic cyst ablation: A critical review (with video) Gastrointest Endosc. 2013;77:526-33.




2020     |     www.medigraphic.com